Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States
The Journal of Prevention of Alzheimer's Disease · 2024-08 · 11 (4) · 983-991
DOI: 10.14283/jpad.2024.68 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Prevention of Alzheimer's Disease, 2024-08. Verfasst von F H Frech und 11 weiteren Autor:innen. Beteiligte Einrichtung: Feride H Frech, PhD, MPH, Senior Director, U.S. HEOR and RWE (Health Economics, Outcomes Research and Real World Evidence) Eisai Inc., 200 Metro Blvd…. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Disease Progression. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND: Limited evidence exists on the economic burden of individuals who progress from mild cognitive impairment (MCI) to Alzheimer disease and related dementia disorders (ADRD). OBJECTIVES: To assess the all-cause health care resource utilization and costs for individuals who develop ADRD following an MCI diagnosis compared to those with stable MCI. DESIGN: This was a retrospective cohort study from January 01, 2014, to December 31, 2019. SETTING: The Merative MarketScan Commercial and Medicare Databases were used. PARTICIPANTS: Individuals were included if they: (1) were aged 50 years or older; (2) had ≥1 claim with an MCI diagnosis based on the International Classification of Diseases, Ninth Revision (ICD-9) code of 331.83 or the Tenth Revision (ICD-10) code of G31.84; and had continuous enrollment. Individuals were excluded if they had a diagnosis of Parkinson's disease or ADRD or prescription of ADRD medication. MEASUREMENTS: Outcomes included all-cause utilization and costs per patient per year in the first 12 months following MCI diagnosis, in total and by care setting: inpatient admissions, emergency department (ED) visits, outpatient visits, and pharmacy claims. RESULTS: Out of the total of 5185 included individuals, 1962 (37.8%) progressed to ADRD (MCI-to-ADRD subgroup) and 3223 (62.2%) did not (Stable MCI subgroup). Adjusted all-cause utilization was higher for all care settings in the MCI-to-ADRD subgroup compared with the Stable MCI subgroup. Adjusted all-cause mean total costs ($34 599 vs $24 541; mean ratio [MR], 1.41 [95% CI, 1.31-1.51]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Feride H Frech, PhD, MPH, Senior Director, U.S. HEOR and RWE (Health Economics, Outcomes Research and Real World Evidence) Eisai Inc., 200 Metro Blvd., Nutley, NJ 07110, USA, E-mail: Feride_Frech@eisai.com, Telephone: 1…
Zitieren
APA
Frech, F. H., Li, G., Juday, T., Ding, Y., Mattke, S., Khachaturian, A., Rosenberg, A. S., Ndiba-Markey, C., Rava, A., Batrla, R., De Santi, S., & Hampel, H. (2024). Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States. The Journal of Prevention of Alzheimer's Disease, 11(4), 983-991. https://doi.org/10.14283/jpad.2024.68
Vancouver
Frech FH, Li G, Juday T, Ding Y, Mattke S, Khachaturian A, et al. Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States. The Journal of Prevention of Alzheimer's Disease. 2024;11(4):983-991. doi:10.14283/jpad.2024.68
BibTeX
@article{Frech2024,
author = {Frech, F H and Li, G and Juday, T and Ding, Y and Mattke, S and Khachaturian, A and Rosenberg, A S and Ndiba-Markey, C and Rava, A and Batrla, R and De Santi, S and Hampel, H},
title = {Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States},
journal = {The Journal of Prevention of Alzheimer's Disease},
year = {2024},
volume = {11},
number = {4},
pages = {983--991},
doi = {10.14283/jpad.2024.68}
}
EUVIMED